The inhibition of p65/NF-κB pathway following bivalent IAP antagonist treatment of sensitive cancer cells may offer an explanation as to why bivalent IAP antagonists are more cytotoxic than the structurally related monovalent IAP antagonists. The gene discussed is NFKB1; the disease is cancer.